Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

At Home Use of Noninvasive Vagus Nerve Stimulation Following TBI to Improve Cognition.

16 novembre 2026 mis à jour par: Elliot Roth, Shirley Ryan AbilityLab

Randomized, Sham-controlled Clinical Trial Testing At-home Use of Noninvasive Vagus Nerve Stimulation After TBI

The purpose of this study is to evaluate whether individuals with TBI can comfortably and consistently use transcutaneous vagus nerve stimulation (tVNS) at home and to identify barriers that may affect participation. A secondary objective is to obtain preliminary data to examine whether at-home tVNS is associated with improvement in cognitive skills as well as any improvement in patient reported outcomes such as sleep, mood, or fatigue.

Aperçu de l'étude

Description détaillée

This is a sham controlled pilot study to evaluate the feasibility and preliminary efficacy of remotely supervised, at-home delivery of tVNS in individuals with TBI during the post-acute recovery phase. Eligible participants will complete a 4-week tVNS intervention protocol at home. Mixed methods (quantitative and qualitative) will be used to evaluate outcomes. Eligible participants will be invited to initial baseline assessment and tVNS training session (Visit 1). Then, they will be randomly allocated to recieve either active or sham stimulation for the first two weeks of at-home administration period. They will then return for a min-intervention assessment (Visit 2). After the mid-intervention assessment, they will return home and recieve active stimulation for the remaining two weeks. Lastly, they will return to a post- intervention assessment (Visit 3). In the assessment sessions participants will complete tasks of set shifting and working memory, core executive functions, as well as complete surveys regarding fatigue, sleep, and overall quality of life.

Type d'étude

Interventionnel

Inscription (Estimé)

30

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Illinois
      • Chicago, Illinois, États-Unis, 60611
        • Recrutement
        • Shirley Ryan AbilityLab
      • Chicago, Illinois, États-Unis, 60611
        • Pas encore de recrutement
        • Shirley Ryan AbilityLab
        • Chercheur principal:
          • Elliot Roth, MD
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age 18-75 years Formally diagnosed with traumatic brain injury.
  • Ability to independently use a keyboard.
  • Ability to independently apply the electrode and adjust stimulation or have a designated caregiver available to be trained and assist with these tasks.
  • Able to understand and communicate in English (according to clinical judgment).
  • Able to independently provide consent to participate. -Able to come in person to Shirley Ryan AbilityLab in Chicago, IL for three visits over 5 weeks.

Exclusion Criteria:

  • Acute medical issues requiring close physician or nursing monitoring. Bioelectrical implants, cerebral shunts, including pacemakers.
  • Anyone with sore or diseased skin area in the ear
  • Pregnancy or persons who are lactating.
  • Cardiac arrhythmia.
  • Epilepsy or seizure disorders.
  • Significant gross or fine motor weakness.
  • Significant, ongoing communication or comprehension impairments (such as aphasia) that would affect an individual's ability to complete the required assessments.
  • Severely impaired memory retention
  • Current major depression diagnosis.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Active Stimulation

Initial baseline assessment completed Day 0. Active stimulation using Tancutaneous Vagus Nerve Stimulation (tVNS) device , for atleast one hour a day for 14 days at home (Day1-14). A mid intervention assessment session completed on Day 15. Following that assessment, another two weeks (Day 16-29) of active stimulation at home followed by a post intervention assessment session.

tVNS stimulation at home for atleast one hour a day for 4 weeks.

Comparateur factice: Sham Stimulation

Initial baseline assessment completed Day 0. Sham stimulation using Tancutaneous Vagus Nerve Stimulation (tVNS) device, for atleast one hour a day for 14 days at home (Day1-14). A mid intervention assessment session completed on Day 15. Following that assessment, participant will switch to recieve active stimulation for the remaining 2 week at home (Day 16-29) followed by a post intervention assessment session.

Participants will recieve two weeks of sham stimulation for atleast one hour a day, followed by 2 weeks of active stimulation for atleast one hour a day.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
Recording the number of participant who completed at least 75% of the sessions out of the number of participants enrolled in the study.
Délai: Post Intervention Assessment Day 30
Post Intervention Assessment Day 30
Semi-structured interviews will collect feedback on perceived benefit, usability, logistical challenges, and barriers to adherence.
Délai: Post Intervention Assessment Session Day 30
Post Intervention Assessment Session Day 30

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
N-Back
Délai: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

In the N-Back Task, participants are presented a series of visual stimuli. They are asking for each stimulus whether is matches a stimulus n-trials before. For example, in a 2-back task, in which the trials consist of letters, participants have to decide whether the current letter is the same as the letter in the trial n-2. We will use a computerized version of this task.

Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
California Verbal Learning Test
Délai: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

The California Verbal Learning Test evaluates the ability to encode, recall, and recognize verbally presented information across multiple learning trials and delayed recall conditions. Participants are read multiple lists of words and asked to recall specific words at different time allotments.

Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
Trail Making A&B
Délai: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

Trail Making Part A requires participant to draw a line between circles containing numbers in ascending order. Part B requires participants to alternate drawing a line between ascending letters and numbers. The key measures are the time required to complete and the number of errors made in Part A and Part B. The test measures various aspects of cognition including attention, visual search, motor coordination, reasoning, and task switching.

Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
Conners Continuous Performance Test 3rd Edition
Délai: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

CPT-3 is a computerized task requires of pressing the space bar on a computer keyboard after any letter is presented on the screen, except for the letter "X". This test lasts about 14 minutes. It measures several aspects of sustained attention, including inattention, impulsivity, and vigilance captured by measuring response styles, errors, and response times.

Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 décembre 2026

Achèvement primaire (Estimé)

1 décembre 2028

Achèvement de l'étude (Estimé)

1 mars 2029

Dates d'inscription aux études

Première soumission

16 novembre 2026

Première soumission répondant aux critères de contrôle qualité

16 novembre 2026

Première publication (Réel)

20 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner